About OncoGenex



FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment

Wednesday, Jun 10 2015

OncoGenex Announces Data from Borealis-1™ Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer

Monday, Jun 1 2015

OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis

Saturday, May 30 2015

OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting

Wednesday, May 20 2015

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015

Thursday, May 14 2015

OncoGenex to Report First Quarter 2015 Financial Results on May 14, 2015

Monday, May 4 2015

OncoGenex Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC

Thursday, Apr 30 2015


External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue